<DOC>
	<DOCNO>NCT02397915</DOCNO>
	<brief_summary>The purpose study provide information whether subject allergic rhinitis ( AR ) prefer administration fluticasone furoate ( FF ) nasal spray mometasone furoate ( MF ) nasal spray base product feel subject administer . This Phase IV interventional study multi-center , randomize , double-blind , single-dose , cross-over subject preference study evaluate compare patient preference FF [ ( total dose 110 microgram ( mcg ) ] MF ( total dose 200 mcg ) nasal spray subject allergic rhinitis . These two commonly use nasal spray use different actuation system ( FF nasal spray side-actuated ; MF nasal spray top-actuated ) study evaluate whether difference reflect patient-assessed attribute two nasal spray . The attribute property assess subject nasal spray include smell , taste &amp; aftertaste , drip throat , run nose , urge sneeze , irritation . The single-day study per subject comprises screen treatment procedure . Eligible subject randomize 1:1 cross-over treatment schedule subject receive product . One group subject two spray FF administer nostril whilst second group two spray MF administer nostril . At 30 ( ± 5 ) minute first study medication treatment , two group switch . The first group two spray MF administer nostril second group two spray FF administer nostril . After treatment subject complete two set attribute questionnaire ( 'immediate ' 'delayed ' ) . A subject-rated 'immediate ' attribute questionnaire complete immediately follow treatment subject-rated 'delayed ' attribute questionnaire complete approximately 2 minute treatment . Upon completion second set two attribute questionnaire ( immediate delay ) , preference questionnaire complete subject . In preference questionnaire , subject state prefer treatment , , product attribute , finally state overall preferred treatment , . There follow-up contact subject 24 ( ± 4 ) 96 ( ± 4 ) hour administration last treatment . The study plan enroll 300 subject .</brief_summary>
	<brief_title>Patient Preference Study Fluticasone Furoate Mometasone Furoate Nasal Sprays</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female subject 18 65 year age , inclusive time signing informed consent . Severity disease : Subjects meet criterion may also vasomotor rhinitis eligible study . A positive skin test perennial ( example , limit , animal dander , house dust mite , cockroach , mould ) / seasonal ( example , limited , grass , tree , weed , ragweed ) allergen within 12 month prior Screening . If subject test 12 month prior Screening , positive skin test ( prick method ) require Screening . A positive skin test define wheal &gt; =3 millimeter ( mm ) large diluent control prick testing . In vitro test specific Immunoglobulin E ( IgE ) [ radioallergosorbent test ( RAST ) , paper radioimmunosorbent test ( PRIST ) ] allow diagnosis AR . A female subject eligible participate pregnant [ confirm negative urine ( prefer ) serum human chorionic gonadotrophin ( hCG ) test ] , lactate , least one follow condition applies : ( ) Nonreproductive potential define premenopausal female document tubal ligation document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion hysterectomy document bilateral oophorectomy ; postmenopausal define 12 month spontaneous amenorrhea . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . ( b ) Reproductive potential agrees follow one option list GlaxoSmithKline ( GSK ) modify list highly effective method avoid pregnancy female reproductive potential ( FRP ) requirement 30 day prior first dose study medication least 4 day last dose study medication . The GSK modify list highly effective method include : contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral contraceptive ; either combine progestogen alone ; Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch ; Male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject . This list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse long term persistent basis . A male subject eligible participate ( ) subject female partner child bear potential comply follow contraception requirement time first dose study medication least 4 day last dose study medication ; ( b ) Vasectomy documentation azoospermia ; ( c ) Male condom plus partner use one contraceptive option : Contraceptive subdermal implant meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral contraceptive , either combined progestogen alone , Injectable progestogen ; Contraceptive vaginal ring ; Percutaneous contraceptive patch . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Understanding questionnaire : In opinion investigator , subject posse degree understand write questionnaire enables subject complete study participation . Informed consent : Capable give sign informed consent include compliance requirement restriction list consent form protocol . Concurrent condition / Medical History : Concomitant medical condition define limited historical current evidence clinically significant uncontrolled disease body system ( e.g. , tuberculosis , psychological disorder , eczema , uncontrolled diabetes , immunosuppression ) . Significant defined disease , opinion investigator , would put safety subject risk study participation , compromise scientific validity study ; A respiratory infection time study participation ; A condition associate anosmia ( loss smell ) ageusia ( loss taste ) within 2 week study may selfreported condition experienced subject ; Clinical evidence Candida infection nose oropharynx ; Acute rhinosinusitis within 60 day screen ; Current severe physical obstruction nose ( e.g. , deviated septum nasal polyp ) nasal septal perforation nasal trauma nasal ulcer ; History haemorrhagic diathesis , atrophic rhinitis , recurrent nasal bleeding may , opinion investigator , impact safety subject scientific validity study ; Nasal biopsy within 60 day screen ; Nasal jewellery piercings could impact nasal safety airway resistance ; Rhinitis medicamentosa within 60 day screen ; History glaucoma , cataract raise intraocular pressure . Concomitant medication : Use intranasal corticosteroid ( FF , MF others ) within 4 week study participation ; Recent ongoing use corticosteroid nonnasal route , opinion investigator , could preclude subject participation study ; Use intranasal medication ( include intranasal antihistamine , intranasal decongestant , intranasal saline ) within 1 week study participation ; Use medication , opinion investigator , could disturb taste smell faculty subject ; Use medication significantly inhibit cytochrome P450 ( CYP ) subfamily CYP3A4 , include limited ritonavir ketoconazole , within 4 week study participation . Relevant habit : Use perfume strongsmelling cosmetic product oral rinse similar product study day could , opinion investigator , compromise participation study . Subjects notified criterion prior study participation ; Use tobacco , inhaled oral nicotinecontaining product , allow 12 hour prior start dose . Contraindications : History sensitivity study procedure medication , component thereof , history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Diagnostic assessment criterion : Positive pregnancy test female breastfeeding ; The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) , unless stringent local guideline need follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nasal Spray</keyword>
	<keyword>Fluticasone Furoate</keyword>
	<keyword>Attributes</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Mometasone Furoate</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Preference</keyword>
</DOC>